Johnson & Johnson (JNJ) Dividends

Johnson & Johnson's dividend is a cornerstone of its shareholder returns. The dividend yield of 2.14% is slightly below the broader healthcare sector average, which often ranges closer to 2.5-3.0%, but is compensated by a strong track record of growth. The company's dividend sustainability is supported by a robust financial profile. The payout ratio, based on the provided EPS of $11.03, is approximately 46%, which is a moderate and manageable level, leaving ample room for reinvestment and cushion during downturns. This aligns with the Quality Indicators in the framework, specifically the strong balance sheet, evidenced by a Debt/Equity ratio of 0.59, which is well below the framework's cautionary threshold of 1.0x Debt/EBITDA. Free cash flow generation is sufficient, with an FCF Yield of 3.4% covering the dividend yield, indicating the payout is funded by genuine business earnings rather than debt. The company has a long history of increasing its dividend, and the 9.1% YoY revenue growth suggests an underlying business capable of supporting future hikes. For a value investor, the combination of a sustainable payout, a fortress balance sheet, and a culture of returning capital is favourable. Analysis based on data as of 2024-05-15.